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Abstract
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most prevalent of the human prion dis-
eases, which are fatal and transmissible neurodegenerative diseases caused by the infec-
tious prion protein (PrPSc). The origin of sCJD is unknown, although the initiating event is
thought to be the stochastic misfolding of endogenous prion protein (PrPC) into infectious
PrPSc. By contrast, human growth hormone-associated cases of iatrogenic CJD (iCJD) in
the United Kingdom (UK) are associated with exposure to an exogenous source of PrPSc. In
both forms of CJD, heterozygosity at residue 129 for methionine (M) or valine (V) in the
prion protein gene may affect disease phenotype, onset and progression. However, the rel-
ative contribution of each PrPC allotype to PrPSc in heterozygous cases of CJD is unknown.
Using mass spectrometry, we determined that the relative abundance of PrPSc with M or V
at residue 129 in brain specimens from MV cases of sCJD was highly variable. This result is
consistent with PrPC containing an M or V at residue 129 having a similar propensity to mis-
fold into PrPSc thus causing sCJD. By contrast, PrPSc with V at residue 129 predominated in
the majority of the UK human growth hormone associated iCJD cases, consistent with
exposure to infectious PrPSc containing V at residue 129. In both types of CJD, the PrPSc
allotype ratio had no correlation with CJD type, age at clinical onset, or disease duration.
Therefore, factors other than PrPSc allotype abundance must influence the clinical progres-
sion and phenotype of heterozygous cases of CJD.
Author Summary
In Creutzfeldt-Jakob disease (CJD), heterozygosity at residue 129 for methionine or valine
in normal prion protein may affect disease phenotype, onset and progression. However,
the relative contribution of each prion protein allotype to the infectious, disease associated
form of prion protein (PrPSc) is unknown. Here we report the novel observation that in
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heterozygous cases of sporadic CJD the PrPSc allotype ratio is highly variable. This case-
by-case variability is consistent with the origin of sporadic CJD being the spontaneous, but
random, misfolding of either host prion protein allotype into infectious PrPSc. By contrast,
in heterozygous cases of iatrogenic CJD in the United Kingdom resulting from exposure
to contaminated human growth hormone, the PrPSc allotype ratio is much more homoge-
neous and consistent with exposure to infectious PrPSc containing valine at residue 129.
Surprisingly, the PrPSc allotype ratio did not correlate with disease onset or duration in
either disease type. Thus, factors other than PrPSc allotype ratio likely influence the clinical
progression of heterozygous cases of CJD. Moreover, our results suggest that the ratio of
methionine to valine in PrPSc may be a means of determining the origin of prion infection.
Introduction
Prion diseases are fatal neurodegenerative disorders affecting humans and various other mam-
mals. They are associated with the misfolding of monomeric prion protein (PrPC) into a patho-
logical isoform termed PrPSc that is partially protease resistant, aggregated, and infectious.
Human prion diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Schein-
ker syndrome (GSS), kuru, fatal familial insomnia (FFI) (for review, see [1]), PrP cerebral amy-
loid angiopathy [2] and variably protease-sensitive prionopathy [1, 3]. Although CJD occurs in
sporadic, genetic, and iatrogenic forms, the most common form is sporadic CJD (sCJD), which
occurs at approximately 1–2 cases per million people per year in any given population.
Acquired forms of CJD such as kuru, variant CJD, and iatrogenic CJD (iCJD), represent a
smaller percentage of all CJD cases.
CJD is associated with a wide diversity of clinicopathological features [1, 4, 5], but the fac-
tors that determine these different CJD phenotypes are still being elucidated. Sporadic CJD is
classified by a neuropathological profile that appears to correlate with the biochemical proper-
ties of PrPSc [4–7] as well as the sequence of the patient prion protein gene (PRNP) at codon
129. All three genotypes of a naturally occurring amino acid polymorphism at PRNP codon
129 are found in CJD: homozygous methionine (MM) or valine (VV), and heterozygous (MV).
Biochemically, the two major PrPSc types associated with CJD, termed Type 1 and Type 2, can
be distinguished by the molecular mass of PrPSc following protease digestion. Type 1 PrPSc has
a protease-resistant molecular mass of approximately 21 kDa while a molecular mass of
approximately 19 kDa is characteristic of Type 2 PrPSc [1]. Thus, sCJD can occur with six geno-
type/PrPSc type combinations: MM1, MM2, MV1, MV2, VV1, and VV2. These correspond
well to the differing clinicopathological presentation found in patients in the six well-recog-
nized sCJD phenotypic subtypes: MM1/MV1, MM2 cortical, MM2 thalamic, MV2, VV1 and
VV2 [1, 8, 9]. Based on these criteria, as well as transmission studies in non-human primates
[10] and transgenic mice expressing different human PRNP genotypes [11, 12], 5 major strains
of sCJD have been proposed: MM1/MV1, MV2/VV2, MM2c, MM2t and VV1 [5]. PrPSc type
and PRNP genotype are therefore believed to be two major factors influencing CJD phenotype
and pathogenesis.
Although not causing disease itself, the presence of M or V at residue 129 in PrPC does affect
many aspects of prion disease susceptibility and phenotype [1, 4–9, 13]. For example, in a
familial form of human prion disease associated with an aspartic acid to asparagine mutation
at residue 178 (D178N), a methionine in cis at position 129 manifests as FFI, while a valine in
cis at position 129 manifests as CJD [14]. The codon 129 genotype also affects susceptibility to
CJD. Methionine and valine homozygosity at codon 129 are overrepresented in sCJD patients
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when compared to the general population, whereas MV heterozygosity at codon 129 is under-
represented [15–18]. A similar allelic distribution has been observed in human growth hor-
mone associated cases of iCJD in France [19]. The predisposition towards homozygosity in
CJD is even more pronounced in variant CJD, in which all probable and definite clinical cases
reported to date have been MM homozygous [16]. By contrast, MM homozygosity is less com-
mon in human growth hormone associated cases of iCJD in the United Kingdom (UK) in
which heterozygosity and VV homozygosity appear to predominate [19, 20]. Thus, the epide-
miological data suggest that the effect of homozygosity or heterozygosity at codon 129 on CJD
pathogenesis varies depending upon the type of CJD.
There can be considerable variation within heterozygous MV1 and MV2 sCJD patients with
regard to disease duration and onset [6, 9]. This variability may be due to multiple factors
including the relative abundance of different populations of PrPSc. For example, in the brain
the amount of protease-sensitive PrPSc, a conformationally distinct population of PrPSc that is
aggregated but susceptible to digestion with proteinase K [21], has been correlated with disease
progression rate. Multiple forms of PrPSc, including not only Type 1 and Type 2 but also PrPSc
with atypical N-termini, are often found within the same sCJD brain [22, 23] suggesting that
PrPSc type variation may be involved. PrPSc with either M or V at residue 129 (PrPSc-M129 and
PrPSc-V129, respectively) has also been identified in brain material from two different hetero-
zygous sCJD patients [24, 25]. This latter observation is particularly intriguing since the pres-
ence of two different PrP allotypes in the same brain can often lead, in a dose-dependent
manner, to inefficient PrPSc formation and increased disease incubation times [26, 27]. Thus, a
ready explanation for the variability in disease onset and duration in heterozygous cases of CJD
would be quantitative differences between PrPSc allotypes containing M or V at residue 129.
However, the relative abundance of each PrPSc allotype in MV heterozygous cases of sCJD is
unknown.
In order to determine whether differences in CJD phenotype correlated with differences in
the relative amounts of PrPSc-M129 and PrPSc-V129, we extracted protease-resistant PrPSc
from brain tissue of multiple sCJD and iCJD patients heterozygous for M and V at codon 129
in PRNP. Tandem mass spectrometry was then used to differentiate peptides containing M at
residue 129 from those containing V. Our results show that the relative abundance of PrPSc-
M129 and PrPSc-V129 was highly variable between individual sCJD cases. Furthermore, the
PrPSc allotype ratio differed between the sCJD and iCJD patient groups and did not correlate
with CJD type, age at clinical onset, or disease duration.
Results
Differentiation of M and V at residue 129 in human PrP peptides by MS
In previous MS-based analysis of purified hamster and mouse PrPSc, we found that one of the
most commonly identified PrP peptides spanned residues 111–136 (PrP111-136) [28, 29]. This
peptide has also been identified by MS in PrPSc purified from sheep scrapie [30]. In order to
determine if MS analysis could also detect PrP111-136 in human PrPSc, PK treatment followed
by PTA precipitation was used to isolate PrPSc from a sample of brain homogenate from a het-
erozygous case of sCJD. The same procedure was used on brain samples from several non-CJD
neurological controls and the samples were compared. Only 5 PrP-specific peptides were
found in one of the 3 non-CJD controls, indicating that the PrPSc enrichment protocol used
yielded little or no PrPC. By contrast, 525 total PrP peptides were found in the sCJD sample the
most common of which are shown in S1 Table. Many of these peptides spanned the region of
PrP from residues 111–136 and showed variable levels of methionine oxidation (S1 Table).
Importantly, the MV polymorphism at residue 129 was distinguishable based upon the unique
Prion Protein Allotypes in Creutzfeldt-Jakob Disease
PLOS Pathogens | DOI:10.1371/journal.ppat.1005416 February 3, 2016 3 / 21
fragmentation patterns of peptides containing either M or V (Fig 1a and 1b). The same
PrP111-136 peptides were also found, albeit with a much lower rate of methionine sulfoxida-
tion, using rHuPrP-M129 and rHuPrP-V129 purified from E. coli (S1a and S1b Fig). Analysis
of synthetic PrP111-136 peptides containing either M or V at residue 129 confirmed that each
peptide yielded distinctive spectra with precise differences between MS/MS fragments corre-
sponding to the presence of either M or V at residue 129 (S1c and S1d Fig). Finally, MS analysis
using purified rHuPrP demonstrated that PrP111-136 peptides containing M or V at residue
129 could be differentiated with 100% specificity (S2 Fig).
Semi-quantitative analysis of peptides containing M or V at residue 129
in human PrP
The detection of peptides with either M or V at residue 129 in PrPSc from a heterozygous case
of sCJD (Fig 1) confirmed earlier studies demonstrating the presence of both PrPSc allotypes in
two cases of heterozygous sCJD [24, 25]. Therefore, both PrPSc-M129 and PrPSc-V129 might
contribute to sCJD pathogenesis. However, the relative abundance and thus potential extent of
the contribution of each allotype to disease pathogenesis is unknown. Spectral counting, which
is defined as the number of MS spectra identified for a protein, is a semi-quantitative technique
that is often used as a practical method for estimating protein abundance [31]. It provides a
robust label-free estimate for comparing the relative abundance of proteins in or between sam-
ple groups [32]. We first determined the quantitative relationship between PrP concentration
and spectral counts using MS analysis of a solution of purified rHuPrP stoichiometrically
adjusted to contain different molar ratios of rHuPrP-M129 and V129 (S2 Fig). There was a
good correlation between spectral counts and the concentration of rHuPrP-M129 (R2 = 0.89).
At a molar ratio of 50:50, 56 ± 2% of the PrP111-136 peptides were identified as M129 while
approximately 44 ± 2% contained V129. Thus, spectral counting allowed us to estimate the rel-
ative abundance of M or V at residue 129 in a heterozygous mixture of human PrP, albeit with
a slight bias towards detection of the M versus the V PrP111-136 peptide. Therefore, we used a
spectral counting approach to semi-quantitatively determine the relative amounts of PrPSc-
M129 and PrPSc-V129 in brain tissue derived from heterozygous cases of sCJD.
Variable abundance of M and V at residue 129 in PrPSc isolated from
sCJD brain
Patient brain samples from 14 cases of heterozygous sCJD were analyzed and their clinical and
molecular data are presented in Table 1. The prominent neuropathological features of each
case are described in S2 Table and exemplified by images of PrP immunohistochemistry per-
formed on cerebral cortex (CC) and, where relevant to this study, cerebellar cortex (CbC) sam-
ples (Fig 2a). No PrPSc is detected in non-CJD brain using this technique (for an example see
S3a Fig). The pathological and molecular features correspond broadly to the histopathological
types proposed by Parchi et al [5]. However, in certain cases, such as case 3, there was a dis-
crepancy between molecular and histopathological findings (see S2 Table) suggesting an atypi-
cal case of MV1 sCJD. Age of onset for the sCJD cases analyzed ranged from 53–77 years
(mean ± SD = 64.7 ± 7.3) while disease duration ranged from 4–21 months
(mean ± SD = 10.9 ± 5.7). Molecular analysis had previously identified 5 of the cases as being
of the MV1 sCJD subtype (cases 1–5) and 9 as being of the MV2 sCJD subtype (cases 6–14)
(Table 1). Western blot analysis comparing a sample from the specimen used for MS (Fig 3a,
middle lane of each blot) to reference standards for Type 1 PrPSc from sCJD MM1 (Fig 3a, left
lane of each blot) and Type 2 PrPSc from sCJD VV2 (Fig 3a, right lane of each blot) confirmed
the expected presence of Type 1 or Type 2 protease-resistant PrP in these samples. Analysis of
Prion Protein Allotypes in Creutzfeldt-Jakob Disease
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Fig 1. Methionine and valine polymorphism at residue 129 in human PrP can be distinguished by mass spectrometry. Representative MS/MS
spectra of human PrP peptide 111–136 with methionine (a) or valine (b) at residue 129 (underlined). The spectra are derived from a PK-treated, PTA-
precipitated brain homogenate from sCJD case 10. The PrP111-136 MS/MS spectra were extracted from the raw data using the Data Analysis program v4.0
provided by Agilent. Ion scores of 130 and 127 were assigned by MASCOT for the M129 and V129 PrP111-136 peptides, respectively. Peaks were
visualized using Scaffold v4.3 (Proteome Software, Portland, OR). The peptide sequence, charge state and observedm/z value for the MS1 ion are shown
above each mass spectrum. Italicized methionine residues 112 and 129 in panel A and methionine 112 in panel B are oxidized in this representative
example. Those fragment ions for which them/z value changed depending upon the polymorphism at residue 129 are shown in red and those ions withm/z
values unaffected by the changes at residue 129 are shown in blue. Them/z values shown are the experimentally observed values and deviate slightly from
the values calculated in silico according to the mass accuracy of the instrument used in this study.
doi:10.1371/journal.ppat.1005416.g001
Prion Protein Allotypes in Creutzfeldt-Jakob Disease
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samples from one sCJD MV1 case specimen consistently showed a mobility slightly ahead of
the Type 1 reference standard (Fig 3a, case 4). The blots further resolved the presence of a Type
2 doublet (2d) in 6 out of the 9 MV2 subtype cases (Table 1 and Fig 3a). The relative amounts
of the two doublets varied between samples from equivalence (case 10 CC) to barely detectable
amounts of the least abundant band (case 7 CC). None of the sCJD specimens examined con-
tained both Type 1 and 2 PrPSc (Fig 3a). No PrPSc is detectable in PK-treated non-CJD brain
using this technique (for an example see S3b Fig).
PrPSc enriched from the cerebral cortex or cerebellar cortex of the 14 cases of heterozygous
sCJD as well as 3 non-CJD neurological controls was analyzed by MS. For each patient sample,
the number of PrP spectra spanning residues PrP111-136 was determined. Using the data anal-
ysis criteria described in the materials and methods, an average of>5 PrP111-136 spectra were
identified in every sCJD sample examined but not in the non-CJD controls. The abundance of
PrPSc-M129 relative to PrPSc-V129 varied between MV1 samples (Fig 3b and Table 1), ranging
from 100% to 34% of the total PrPSc detected. Similar results were obtained for the MV2 sam-
ples where the percentage of PrPSc-M129 ranged from 88–22% (Fig 3b and Table 1). For each
sCJD molecular type approximately 20–30% of the cases significantly favoured PrPSc-M129,
20–30% favoured PrPSc-V129, and all other cases had an equal distribution of PrPSc-M129 and
PrPSc-V129 (Fig 3b).
Table 1. Clinical andmolecular features of heterozygous (MV) CJD cases analyzed.
Case ID Number Gender Age at Onseta Durationb Molecular Sub-classiﬁcation Brain Regionc PrPSc Typed M129 (%)e
1 M 75 5 sCJD MV1 CC 1 61 ± 3
2 M 77 4 sCJD MV1 CC 1 59 ± 2
3 M 62 14 sCJD MV1 CC 1 98 ± 3
CbC 1 100 ± 0
4 M 64 14 sCJD MV1 CC 1f 34 ± 5
5 F 53 4 sCJD MV1 CC 1 57 ± 3
6 F 61 13 sCJD MV2 CC 2d 85 ± 13
7 F 62 21 sCJD MV2 CC 2d 38 ± 18
CbC 2 22 ± 9
8 M 75 8 sCJD MV2 CC 2 88 ± 14
9 M 65 21 sCJD MV2 CC 2d 82 ± 8
CbC 2d 33 ± 8
10 F 60 14 sCJD MV2 CC 2d 43 ± 2
11 M 72 7 sCJD MV2 CC 2 85 ± 1
12 F 64 13 sCJD MV2 CC 2 29 ± 20
13 F 59 18 sCJD MV2 CC 2d 58 ± 11
14 M 57 15 sCJD MV2 CC 2 62 ± 2
CbC 2d 52 ± 4
aAge of onset in years.
bDisease duration in months.
cCC = cerebral cortex; CbC = cerebellar cortex.
dPrPSc typing according to the method of Parchi et al. [33].
eMean percentage ± SD of PrPSc with M129. There was no signiﬁcant correlation of percentage PrPSc-M129 with sCJD type, age of onset, or disease
duration (p>0.1).
fIn one sCJD MV1 case (ID 4) the mobility of the non-glycosylated PrPSc band was found to be very slightly but consistently greater than that of the Type
1 standard.
doi:10.1371/journal.ppat.1005416.t001
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We next determined if the relative abundance of PrPSc-M129 and PrPSc-V129 could also
vary between brain regions within an individual sCJD patient. The relative abundance of
PrPSc-M129 and PrPSc-V129 in the CbC was compared to that of the CC in one MV1 and
three MV2 sCJD cases (Table 1). There were no major differences in the amount of PrPSc-
Fig 2. Representative neuropathology of heterozygous (MV) sCJD and iCJD patients analyzed. (a) PrP immunohistochemistry performed on sections
of cerebral cortex (CC) or cerebellar cortex (CbC) from sporadic CJD (sCJD) cases 1–5 of the MV1molecular subtype and cases 6–14 of the MV2molecular
subtype. (b) PrP immunohistochemistry performed on sections of cerebral cortex (CC) from iatrogenic CJD (iCJD) cases 16–20 of the MV2molecular
subtype. Original magnifications were X400. The PrP antibody used was the mouse monoclonal antibody KG9 [34].
doi:10.1371/journal.ppat.1005416.g002
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M129 (Fig 4) or the type of PrPSc deposition (Fig 2a) in the cerebral and cerebellar samples
from cases 3 and 7. However, the amount of PrPSc-M129 (Fig 4) as well as the type of PrPSc
deposition (Fig 2a) differed significantly between brain regions in the two other cases, 9 and 14.
While only 4 sCJD cases were analyzed, the data suggest that within the same patient the
Fig 3. The relative abundance of PrPSc containing M at residue 129 is variable and independent of
sCJD type in heterozygous (MV) sCJD patients. (a) Molecular typing of PrPSc from the brain homogenate
of heterozygous sCJD cases 1–14 by the method of Parchi et al. [33]. Each sample (middle lane) is shown
flanked by Type 1 (left lane) and Type 2 (right lane) reference standards from sCJDMM1 and VV2 subtype
cases, respectively. Protease-resistant PrP from all samples was of the A glycotype in which diglycosylated
PrPmonoglycosylated PrP [33]. Case number and brain region are indicated above each blot while PrPSc
type is indicated below. The most informative exposure for the test and reference standard samples from a
series of timed exposures is shown. CC = cerebral cortex; CbC = cerebellar cortex. (b) Relative abundance of
PrPSc-M129 in MV1 and MV2 sCJD. Data are the percent mean ± SD of PrPSc-M129 (black bars) detected in
the CC or CbC (samples 3, 7, 9, and 14 only) of sCJD patients. Each bar represents n = 3–4 technical
replicates except for case 4 where n = 2. A stoichiometrically adjusted solution of 50% rHuPrP-M129 and
50% rHuPrP-V129 (rPrP (50%), hatched bar) was used as a control (n = 8). Statistical analysis was done
using a 1-way ANOVA with Dunnett’s post-test using rPrP (50%) as the control sample. * p = 0.01 to 0.05,
**p = 0.001 to 0.01, ***p = 0.0001 to 0.01, ****p <0.000.
doi:10.1371/journal.ppat.1005416.g003
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amount of PrPSc-M129 and PrPSc-V129 can differ markedly between different regions of the
brain with distinctive neuropathologies.
In order to determine if differences in the amount of each allotype were associated with phe-
notypic variables, the relative abundance of PrPSc-M129 was compared to the sCJD molecular
subtype, age of onset, and duration of clinical disease. Statistical analysis revealed no significant
correlation between the amount of PrPSc-M129 and sCJD molecular subtype, duration, and
age of onset (p> 0.1, Table 1). For example, sCJD MV1 case 3, where 100% of PrPSc was
M129, had a similar age of onset and disease duration to sCJD MV1 case 4 where PrPSc-M129
represented only 34% of the total PrPSc identified (Table 1). Thus, despite significant differ-
ences between cases, the MV ratio of the PrPSc allotypes did not appear to overtly influence dis-
ease onset or progression. There was evidence that PrPSc allotype might influence disease
phenotype in some heterozygous sCJD patients. In two cases, 9 and 14, differences in the PrPSc
allotype ratio between brain regions (Fig 4) were associated with different neuropathologies
(Fig 2a). However, when all of the MV sCJD cases were compared, there was no definitive cor-
relation between the amount of PrPSc-M129 and various neuropathological features such as
the presence of amyloid plaques, pattern of PrPSc deposition or type of spongiform change (S2
Table).
Relative abundance of M and V at residue 129 in PrPSc isolated from
iCJD brain
Next we determined the relative abundance of PrPSc-M129 in brain samples from 6 cases of
iCJD, all of whom were heterozygous at codon 129 in PRNP (see Table 2 for clinical and molec-
ular data). The prominent neuropathological features of each case are described in S2 Table
and exemplified by images of PrP immunohistochemistry performed on cerebral cortex sam-
ples in Fig 2b. The mean age of onset for the iCJD cases was younger than that of the sCJD
cases, ranging from 27–33 years (mean ± SD of 30.3 ± 2.4) while disease duration was longer
than that of the sCJD cases, ranging from 8–32 months (mean ± SD of 17.8 ± 8.5). Western
blot analysis of a tissue sample from the specimen used for MS using the method of Parchi
Fig 4. The relative abundance of PrPSc containing M at residue 129 can vary between brain regions in
heterozygous (MV) sCJD patients.Data are the percent mean ± SD of PrPSc-M129 detected in the CbC
(black bars) or CC (white bars). The case number is indicated under each pair of bars. Each bar represents
n = 3–4 technical replicates except for the CC from cases 7 and 9 where n = 2. Statistical significance was
determined using the unpaired Student’s t-test. *p = 0.01, **p = 0.002.
doi:10.1371/journal.ppat.1005416.g004
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et al. [33] showed that Type 2 PrPSc predominated in all six cases. In 4 of the 6 samples, this
took the form of a Type 2 doublet (2d) and in the other two it was found to be a mixture of
Type 2 and a smaller amount of Type 1 (2+1) (Table 2 and Fig 5a). As with the heterozygous
cases of sCJD, there was no significant correlation between the amount of PrPSc-M129 and dis-
ease duration or age of onset (p> 0.3, Table 2). However, as shown in Fig 5b, 4 of the 6 iCJD
samples had significantly less PrPSc-M129 than PrPSc-V129. When the average relative abun-
dance of each PrPSc allotype for all cases was compared between the sCJD and iCJD groups,
PrPSc-M129 was significantly less abundant in the iCJD cases than in the sCJD cases (p = 0.01
using the unpaired Student’s t-test). Overall, our results suggest that the composition of PrPSc
among MV heterozygous cases of iCJD is less variable and biased towards a higher proportion
of PrPSc-V129 when compared to heterozygous cases of sCJD.
PrPSc allotype ratio and CJD neuropathological subtype
Epidemiological, genetic and neuropathological data all suggest that human growth hormone
associated cases of iCJD in the UK may be the result of contamination with the MV2 or VV2
subtype of sCJD [19, 20]. We therefore compared the PrPSc allotype ratio to the major neuro-
pathological phenotypes represented in both the sCJD and iCJD cases. As with disease onset
and duration, there was no correlation between sCJD PrPSc allotype and Type 1 and Type 2
sCJD cases with similar neuropathological phenotypes (Fig 6). Both the sCJD MV1 + 2C and
MV2K + 2C cases segregated into three distinct groups based on PrPSc allotype ratio with no
significant difference in the mean percentage of PrPSc-M129 between the two types (Fig 6a and
6b). Interestingly, sCJD MV2K and iCJD MV2K had a somewhat similar PrPSc allotype distri-
bution with no statistically significant difference in the mean percentage of PrPSc-M129 (Fig 6c
and 6d). With the caveat that only 2 cases of sCJD MV2K were available for analysis, these data
are nonetheless consistent with the hypothesis that UK cases of human growth hormone asso-
ciated iCJD are the result of exposure to the V2 strain of human prion.
Discussion
Efficient conversion of PrPC to PrPSc can be strongly dependent upon homology at a single
amino acid residue in PrPC [35], including residue 129 [36, 37], and differences in key amino
acid residues can effect disease onset and progression [27, 38, 39]. However, we found no
Table 2. Clinical andmolecular features of heterozygous (MV) iCJD cases analyzed.
Case ID Number Gender Age at Onseta Durationb Molecular Sub-classiﬁcation Brain Regionc PrPSc Typed M129 (%)e
15 M 33 8 iCJD MV2 CC 2d 39 ± 9
16 F 30 12 iCJD MV2 CC 2d 38 ± 14
17 M 32 16 iCJD MV2 CC 2+1 46 ± 3
18 M 28 16 iCJD MV2 CC 2d 36 ± 5
19 F 27 32 iCJD MV2 CC 2d 66 ± 4
20 F 32 23 iCJD MV2 CC 2+1 39 ± 6
aAge of onset in years.
bDisease duration in months.
cCC = cerebral cortex.
dPrPSc typing according to the method of Parchi et al. [33].
eMean percentage ± SD of PrPSc with M129.
There was no signiﬁcant correlation of percentage PrPSc-M129 with iCJD type, age of onset, or disease duration (p>0.3).
doi:10.1371/journal.ppat.1005416.t002
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evidence that M or V at residue 129 in PrPSc correlated with disease onset or progression. This
is consistent with some studies of familial human prion disease which also suggest that disease
phenotype does not necessarily correlate with the presence of M or V at residue 129 in mutant
PrPC [24, 40]. It is possible that, in heterozygous cases of sCJD, the polymorphism at residue
129 does not necessarily lead to protease-resistant PrPSc conformations that are significantly
different. Since PrPSc conformation is thought to encode prion strain phenotypes [1], PrPSc-
M129 and PrPSc-V129 might therefore contribute minimally to conformational differences
affecting disease phenotype. Unknown host factors or other forms of abnormal PrP which may
or may not be equivalently infectious, such as those with atypical protease-digestion profiles
Fig 5. PrPSc containing M at residue 129 is underrepresented in most heterozygous (MV) iCJD
patients. (a) Molecular typing of PrPSc from the brain homogenate of heterozygous iCJD cases 15–20 by the
method of Parchi et al. [33]. Each sample (middle lane) is shown flanked by Type 1 (left lane) and Type 2
(right lane) reference standards from sCJDMM1 and VV2 subtype cases, respectively. Case number and
brain region are indicated above each blot while PrPSc type is indicated below. Protease-resistant PrP from
all samples was of the A glycotype where diglycosylated PrPmonoglycosylated PrP [33]. The most
informative exposure for the test and reference standard samples from a series of timed exposures is shown.
(b) Relative abundance of PrPSc-M129 in MV2 iCJD. Data are the percent mean ± SD of PrPSc-M129 (black
bars) detected in the CC of iCJD patients. A stoichiometrically adjusted solution of 50% rHuPrP-M129 and
50% rHuPrP-V129 (rPrP (50%), hatched bar) was used as a control (n = 8). Each bar represents n = 3–4
technical replicates. Statistical analysis was done using a 1-way ANOVA with Dunnett’s post-test using rPrP
(50%) as the control sample. **p = 0.001 to 0.01.
doi:10.1371/journal.ppat.1005416.g005
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[23] or increased protease-sensitivity [21], may have a more significant influence on age of
onset or duration of clinical disease than the presence of an M or V at residue 129 in Type 1 or
Type 2 PrPSc.
The epidemiological associations of Type 1 PrPSc with methionine homozygosity and Type
2 PrPSc with valine homozygosity within sCJD patient cohorts could be used to argue that the
presence of methionine at position 129 of the prion protein predisposes it to misfold to a Type
1 conformation, whereas the presence of valine at the same position predisposes it to misfold
to a Type 2 conformation. If this were so, then one might predict that Type 1 PrPSc in heterozy-
gous sCJD cases would be largely composed of PrPSc-M129 whereas Type 2 PrPSc in heterozy-
gous sCJD cases would be largely composed of PrPSc-V129 [37]. Data from transmission
studies in transgenic mice [11, 12, 41] and in vitro assays of PrPSc formation [37] are consistent
with this prediction. It was therefore surprising that in our study we saw no correlation
between PrPSc type and PrPSc allotype (Fig 3b). Out of the 5 MV1 sCJD cases analyzed, PrPSc-
M129 was the dominant allotype in only one case while PrPSc-V129 was the most prevalent
allotype in 3 of the 9 MV2 cases analyzed (Fig 3b). It is therefore unlikely that the amino acid
Fig 6. Variable PrPSc allotype ratios in sCJD neuropathological subtypes. The percentage of PrPSc-M129 versus PrPSc-V129 is shown for
neuropathological subtypes for which at least 2 cases were available for comparison. Each point represents the results from a single brain region from a
single patient. For some patients, both CC and CbC were available for analysis. (a) sCJDMV1 + 2C, n = 4 cases, 5 samples total. (b) sCJDMV2K + 2C, n = 6
cases, 8 samples total. (c) sCJDMV2K, n = 2 cases, 3 samples total, (d) iCJDMV2K n = 6 cases. Using the unpaired Student’s t-test, the iCJD MV2K PrPSc
allotype ratio differs significantly from both sCJDMV1 + 2C (p = 0.002) or sCJDMV2K + 2C (p = 0.02) but not from sCJDMV2K (p = 0.07).
doi:10.1371/journal.ppat.1005416.g006
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residue at codon 129 in PrPC predisposes to accumulation of either the Type 1 or Type 2 PrPSc
conformations associated with the MM1/MV1 and VV2/MV2 strains of sCJD.
Despite the distinctive transmission properties of MV1 and MV2 sCJD when inoculated
into transgenic mice expressing human PrPC [11, 12, 41], the sCJD neuropathological pheno-
types MV1 + 2C and MV2K + 2C could not be distinguished based upon their PrPSc allotype
ratios (Fig 6a and 6b). These data are based primarily on the relative abundance of PrPSc-M129
and PrPSc-V129 in the cerebral cortex. It is possible, however, that there may be some correla-
tion with phenotypic differences between brain regions in the same patient. In cases 9 and 14,
where distinctive pathologies were observed in the cerebral cortex and cerebellar cortex (Fig 2),
the PrPSc allotype ratios were also significantly different (Fig 4). By contrast, in two cases where
neuropathology was similar between these two brain regions (cases 3 and 7, Figs 2 and 4), the
PrPSc allotype ratios were also similar. While these data are suggestive that PrPSc allotype may
correlate with regional differences in neuropathology, further analysis of multiple brain regions
from a greater number of patients will be necessary to prove this correlation.
Different strains of sCJD could account for the variability in PrPSc allotype ratio between
patients, although the consistent transmission properties of MV1 and MV2 sCJD into trans-
genic mice expressing human PrPC argues against this [11, 12, 41]. An alternative explanation
for the heterogeneity in the MV PrPSc allotype ratio may lie in its proposed aetiology. In sCJD
the initiating event is thought to be the spontaneous, but stochastic, misfolding of PrPC into
PrPSc. Since either PrPC-M129 or PrPC-V129 could potentially misfold leading to PrPSc accu-
mulation and disease, the PrPSc allotype might be expected to vary from patient to patient.
Such variation is what we observed in our analysis where the relative abundance of PrPSc-
M129 and PrPSc-V129 was independent of sCJD type, differing not only between sCJD cases,
but also between brain regions from a single patient. Thus, our data are consistent with either
PrPC-M129 and/or PrPC-V129 refolding into PrPSc by chance.
Our data may also provide some insight into the relative tendency of PrPC-M129 and PrPC-
V129 to spontaneously adopt the PrPSc conformation. In approximately one-third of all of the
heterozygous sCJD cases analysed, PrPSc-M129 was the most abundant allotype, PrPSc-V129
was the most abundant allotype, or both allotypes were equally represented (Fig 3b). The rela-
tively equal representation of the different possible PrPSc allotypes does not appear to be con-
sistent with one PrPC molecule being more predisposed to misfold into PrPSc than the other, as
has been suggested by several in vitro studies [42–44]. Rather, our data are consistent with
what would be expected if PrPC-M129 and PrPC-V129 were equally likely to spontaneously
misfold into PrPSc. In this context, the differences in relative abundance between the two allo-
types could be interpreted as indicating which PrPC molecule initially misfolded into PrPSc.
Thus, in cases of heterozygous sCJD where PrPSc-M129 predominates, PrPC-M129 could have
misfolded into PrPSc prior to PrPC-V129.
However, it is important to note that we have only analyzed a small portion of the brain
from the end stage of a long and complex disease process. It is more likely that there are multi-
ple variables, both host and prion specific, that contribute to the relative abundance of each
PrPSc allotype at the end stage of disease. For example, the presence of M or V at residue 129 in
PrPC could affect a non-rate-limiting step in PrPSc formation and accumulation which occurs
after the initial misfolding of PrPC. A similar hypothesis was proposed by Hosszu et al. who
reported that methionine or valine at residue 129 had no measurable effect upon the folding,
dynamics, or stability of PrPC [45]. By contrast, there is evidence that there are differences in
the stability of the downstream products of PrPC misfolding. PrPSc from homozygous cases of
sCJD demonstrates a broad spectrum of stabilities [21] while short peptide ‘steric zipper’ struc-
tures derived from homozygous recombinant PrP molecules form more stable crystalline struc-
tures than the hypothetical structures modeled from heterozygous molecules [46]. Therefore,
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while similar free energy barriers for both PrPC-M129 and PrPC-V129 would suggest that they
may be equally likely to misfold into PrPSc, variability in the thermodynamic stability of the
PrPSc end products may be more important in determining the final relative abundance of each
PrPSc allotype.
In contrast with sCJD, the heterozygous cases of iCJD analyzed were more homogeneous,
with a higher proportion of PrPSc-V129 in most of the cases (Fig 5b). As with the sCJD cases,
aetiology may provide an explanation for the greater PrPSc allotype homogeneity of the iCJD
samples. In cases of iCJD prior to 2003 which were linked to human growth hormone therapy
in the UK, 96% had the VV or MV PRNP genotype at codon 129 [19]. In patients diagnosed
after 2008, this percentage had decreased to 86% [20]. Based on the earlier cases, Brandel et al.
[19] first proposed that the UK cases were caused by either sCJD VV2 or sCJD MV2, a conclu-
sion supported by the more recent study [20]. Our data showing that 1) PrPSc-V129 is the
dominant PrPSc allotype in the majority of the UK human growth hormone-associated iCJD
cases analyzed and 2) that the PrPSc allotype distribution between sCJD MV2K and these cases
(Fig 6c and 6d) is very similar, are also entirely consistent with this conclusion.
It is thus possible that the PrPSc-M129 to PrPSc-V129 ratio in heterozygous iCJD patient
cohorts might be a means of determining the prion strain that initiated infection. Unlike sCJD,
iCJD is a secondary infection of CJD in humans. Selective pressures in the original host with
sCJD as well as in the secondary host with iCJD may influence the final PrPSc allotype ratio. If
PrPSc-V129 in the infectious material was of the VV2 type, when transmitted to a second host
it would likely interact most efficiently with PrPC-V129 to form PrPSc. As a result, PrPSc-V129
would more than likely be the predominant PrPSc allotype in the infected iCJD patient. Used in
this way, mass spectrometry analysis of heterozygous PrPSc could be the molecular equivalent
of in vivo traceback studies that have used the transmission properties of iCJD into transgenic
mice [47, 48] or non-human primates [10] to determine the prion strain originally responsible
for infection in groups of patients.
Materials and Methods
Reagents and supplies
Trypsin was purchased from Promega. Burdick & Jackson water and acetonitrile (ACN) were
purchased from VWR. Imperial Coomassie blue stain and iodoacetamide were purchased from
Thermo-Fisher Scientific. Formic acid (FA), dithiothreitol (DTT), trifluoroethanol (TFE),
phosphotungstic acid (PTA), benzonase, and protein extraction reagent (7M urea, 2M thio-
urea, 1% C7BzO, 40 mM Tris, pH 10.4) were purchased from Sigma-Aldrich.
Ethics statement
Human brain samples were obtained from the National CJD Research & Surveillance Unit Brain
and Tissue Bank in Edinburgh, UK, which is part of Edinburgh Brain Banks. For the purposes of
this study, samples were pseudoanonymized using a Brain Bank reference number. Cerebellar
and cerebral cortex tissue from two additional sCJD patients were obtained from the University
of Verona, Italy. These tissues were obtained at autopsy and sent to the Neuropathology Unit at
the University of Verona for statutory definite diagnosis of CJD. All UK cases had consent for
research and their supply and use in this study was covered by LREC 2000/4/157 (National
Creutzfeldt-Jakob disease tissue bank: acquisition and use of autopsy material for research on
human transmissible spongiform encephalopathies, Professor James Ironside, amended date: 9th
October 2007). Ethical approval for the acquisition and use of human brain material was
obtained from the National Institutes of Health (NIH) Office of Human Subject Research
(Exempt #11763 and #12725) and no patient identifiable data was transferred to the NIH.
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Recombinant prion protein (rPrP)
Human recombinant prion proteins spanning residues 23–231 and containing either methio-
nine or valine at residue 129 (rHuPrP-M129 and rHuPrP-V129, respectively) were cloned into
a pET41a vector using NdeI-XhoI restriction enzymes. The proteins were expressed as inclu-
sion bodies using Escherichia coli Rosetta cells and then purified as described for recombinant
hamster PrP [49]. Briefly, guanidine denatured PrP from bacterial inclusion bodies was clari-
fied by centrifugation, bound to NiNTA resin (Qiagen), and then subjected to on-column
refolding without reducing agents using a non-denaturing refolding buffer (10mM Tris,
100mM sodium phosphate, pH 8). After elution using refolding buffer adjusted to pH 5.8 and
500mM imidazole, PrP was immediately sterile-filtered, dialyzed into 10mM ammonium for-
mate pH 4.5, and stored at -80°C at a concentration of ~0.3mg/mL until needed. Consistent
with our previous results [49], all PrP preparations were approximately 99% pure. In addition,
the molecular weight of purified recombinant PrP was verified by intact mass analysis using a
Sciex 4000 QTrap system.
PrP peptides
Synthetic PrP111-136 peptides containing either M or V at residue 129 were diluted in water
with 3% ACN/0.1% formic acid and used without further modification after having been sub-
jected to HPLC and MALDI in order to establish purity and the correct molecular weight.
Allotype ratio concentration curve
Concentrations of purified rHuPrP-M129 and rHuPrP-V129 proteins were determined indi-
vidually by absorbance at 280nm and then adjusted to contain molar ratios of 0:100, 25:75,
50:50, 75:25, or 100:0 rHuPrP-M129 to rHuPrP-V129, respectively. Final mixtures containing
0.3mg/mL total rPrP were mixed 1:1 with 2X sample buffer (Life Technologies), boiled for 5
min and subjected to SDS-PAGE. Coomassie blue staining displayed a single strong band
which was excised and subjected to in-gel trypsin digestion as described below. At least 8 lanes
(n = 8–9) were used per individual rPrP mixture and each was subjected to mass spectrometry
analysis as described below.
Human brain tissue
Approximately 2g samples of cerebral cortex (CC) and (in some cases) cerebellar cortex (CbC)
from sCJD, iCJD and non-CJD neurological controls were analysed. All cerebral cortex samples
were of grey matter enriched frontal cortex with the exception of cases 3 and 14 which were
from the occipital cortex. Additionally, grey matter enriched cerebellar cortex samples were
analyzes from cases 3, 7, 9 and 14. The choice of frontal cortex reflects both its involvement in
MV1 sCJD, MV2 sCJD, and UK human growth hormone-related MV iCJD as well as tissue
availability. The selection of cerebellum as a second region to analyze was based on it providing
a contrast to the cerebral cortex as well as the known pronounced involvement of the cerebel-
lum in MV2 sCJD.
The diagnosis of definite sCJD or definite iCJD had previously been reached using interna-
tionally recognised criteria (http://www.cjd.ed.ac.uk/documents/criteria.pdf) and the cases had
been characterised in terms of their neuropathology, PRNP codon 129 genotype, and predomi-
nant PrPSc type. The 20 CJD cases examined comprised 14 cases of sCJD in heterozygous
patients (5 of the MV1 and 9 of the MV2 molecular subtypes) and 6 cases of iatrogenic CJD in
heterozygous patients (all of which were of the MV2 molecular subtype). The three non-CJD
neurological cases analyzed were initially suspected of having CJD, but post mortem
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examination resulted in an alternative diagnosis. These three patients were a 78 year old male
with a pathological diagnosis of Lewy body dementia, a 66 year old female with a pathological
diagnosis of arteriosclerosis and a seventy year old female with a pathological diagnosis of arte-
riosclerosis. Western blot analysis had previously failed to detect PrPSc in the brain in these cases
and the PRNP codon 129 genotypes of the three patients were VV, MV andMM respectively.
Neuropathological review
A detailed neuropathological review of the sCJD and iCJD cases analysed in this study was con-
ducted and cases were sub-classified with reference to the sCJD histotypes reported by Parchi
et al [5].
Western blot analysis and typing of PrPSc
To confirm the presence of PrPSc and to provide a definitive type for the PrPSc present in the
brain specimen being used for mass spectrometry, a 100mg tissue sample was removed from
each brain specimen and analysed by western blotting. The stringent sample preparation and
proteinase K digestion conditions of Parchi et al 2009 were used [33] that allow distinction to
be made between Type 1 (1), Type 2 (2), a mixture of Type 2 and Type 1 (2+1) and doublets of
Type 2 (2d).
Enrichment of PrPSc using phosphotungstic acid
Brain tissue samples for mass spectrometry were homogenized in phosphate buffered saline
(PBS, pH 7.4) to a final concentration of 20% (w/v) using a Mini-BeadBeater-8 (Biospec) and
stored in aliquots at -80°C until needed. Enrichment of PrPSc was performed using PTA pre-
cipitation as described previously [50] with some modifications [51]. Briefly, 250 μL of a 20%
brain homogenate was diluted to 10% with PBS and then mixed with 500μL of 4% sarkosyl/
PBS. Following incubation at 37°C for 30 min, samples were treated with benzonase at 50U/
mL for 1 hour and then clarified by a 5 min centrifugation at 5,000 g. The supernatants were
then digested with PK (50 μg/mL) for 1 hour at 37°C. PTA was added to a final concentration
of 0.3% (w/v) and the sample incubated at 37°C for 2 hours. Samples were centrifuged for 30
min at 16,100 x g, the pellets suspended in 200μL of PBS with 200mM EDTA, incubated at
37°C for 30 min, and centrifuged as before. The pellets were resuspended in 200μL PBS, incu-
bated at 37°C for 30 min, and the sample again collected by centrifugation. The final pellet was
used for analysis of PrPSc by mass spectrometry as detailed below.
Reduction, alkylation and tryptic digestion of PrPSc
Samples of PrPSc pelleted by PTA precipitation were solubilized in 25μL of protein extraction
reagent (7M urea, 2M thiourea, 1% C7BzO) and DTT added to a final concentration of 14mM.
Following a 30 min incubation at 37°C, iodoacetamide was added to a final concentration of
75mM and the sample incubated in the dark at room temperature for 30 min. The reaction was
quenched by the addition of 1M DTT to a final concentration of 200mM followed by the addi-
tion of 12μL of 4X NuPAGE sample buffer (Life Technologies). Denatured, reduced and alkyl-
ated samples of enriched PrPSc were briefly heated to 100°C using a heating block prior to
loading onto a 10% Bis-Tris 1.5mm gel for SDS-PAGE. Gels were stained with Coomassie blue
(Imperial stain, Thermo-Fisher Scientific) but the bands corresponding to PrPSc were often too
faint to be detected by eye. Therefore, the area of the gel lane encompassing molecular mass
markers from ~10kDa to 80kDa, including the area of the gel containing PrPSc, was divided
into 8 gel slices. In-gel trypsin digestion was then performed as described previously [28]. Each
Prion Protein Allotypes in Creutzfeldt-Jakob Disease
PLOS Pathogens | DOI:10.1371/journal.ppat.1005416 February 3, 2016 16 / 21
patient sample was analyzed at least 3 times (i.e. 3 technical replicates) as detailed above except
for the CC from cases 4, 7 and 9 where only two technical replicates were done. Thus, each
technical replicate was composed of 8 individual LC-MS/MS runs corresponding to 8 gel slices
excised from a single lane of the Commassie blue stained gel.
HPLC chip-based nanospray tandemmass spectrometry
Trypsin-digested peptides were identified by LC-MS/MS (abbreviated as MS throughout the
manuscript) using an Agilent 1200 HPLC system interfaced with a 6330 XCT Ultra Ion Trap
via a chip-cube nanospray source. The mass spectrometer was externally calibrated using a tun-
ing mix provided by Agilent. Data-dependent MS acquisition was performed with dry gas
(purified air) set to 4L/min at 350°C, MS capillary voltage 1800V, and a maximum accumula-
tion time of 150ms. The MS scan range was set to 300–1400 m/z in the Ultrascan mode. Four
parent ions were selected for each MS/MS cycle with a fragmentation amplitude of 1.0V. Pro-
tein digests were loaded onto the HPLC chip (Agilent #G4240-62006, Zorbax 300SB-C18,
5μm, 75μm x 150mm) with an autosampler and washed with Buffer A (3% ACN/H2O and
0.1% FA) prior to elution at 300nL/min by reverse-phase chromatography. The gradient was
3–30% Buffer B (90% ACN and 0.1% FA) over 30 min, to 50% B by 40 min, 80% B by 50 min,
90% B by 60 min, 97% B by 70 min, and back to 3% B by 78 min. This run was followed by a 4
min post-run re-equilibration at 3% B with a total run time of approximately 80 min.
Data analysis
Raw data were processed into MGF peak lists using MASCOT Distiller v2.4.3.0. The MGF files
were searched using MASCOT Daemon against a target database (www.uniprot.org) filtered
for human taxonomy consisting of 20,235 entries which included an entry for PrP111-136 con-
taining V at residue 129 in addition to the default Swiss-Prot entry containing the full PrP
sequence with M at residue 129. The trypsin/P search parameters for MASCOT protein identi-
fication consisted of one missed tryptic cleavage allowed with a fixed carbamidomethylation
(+57, Cys) and a variable oxidation (+16, Met). Mass tolerances of 2.0 and 1.0 Daltons were
used for parent and monoisotopic fragment ions, respectively. The resulting DAT files gener-
ated by MASCOT were used as input files for spectral counting using the ProteoIQ bioinfor-
matics platform (Premier Biosoft Inc) [52] with the constraints that only MASCOT ion scores
of 30 and only peptides of 7 amino acids in length were considered in these calculations.
The number of PrP spectra from each sample were then compared to the other samples that
had been processed using the same protocols and the same instrument parameters.
In PTA precipitates from the 3 non-CJD brains examined, only 5 PrP peptides were
detected in a single sample following a total of 72 MS runs. This indicated that little or no PrPC
was present in the final non-CJD PTA pellet. A background threshold of5 total PrP peptides
was therefore used to exclude any potential contribution of PrPC to the final PTA pellet and all
3 non-CJD samples were considered negative for PrPSc. By contrast, all PTA precipitated sCJD
and iCJD samples had total PrP spectral counts at least 26-fold above the background threshold
of 5 spectral counts. Only western blot positive samples yielding greater than 5 PrP111-136
peptides were utilized for semi-quantitation as spectral counts of less than 5 spectra are consid-
ered to be unreliable for spectral counting [32, 53].
Statistics
Mean and standard deviation (SD) were derived using the individual technical replicates
described above. The percentage of PrPSc-M129 and PrPSc-V129 was calculated by dividing the
number of peptides containing M129 or V129 by the total number of peptides containing
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residue 129 and multiplying by 100. The statistical significance of multiple data sets was deter-
mined using a 1-Way ANOVA with Dunnett’s post-test. A 50:50 mix of rHuPrP-M129
rHuPrP-V129 was set as the control group. The potential relationship between disease onset or
duration and the percentage of PrPSc containing M at residue 129 was analyzed by determining
the Pearson correlation coefficient r using correlation analysis. The unpaired Student’s t-test
was used to analyze the percentage of PrPSc-M129 between different brain regions and the per-
centage of PrPSc-M129 in sCJD versus iCJD. All calculations were done using the GraphPad
Prism software package, version 6.04.
Supporting Information
S1 Fig. Coverage of human PrP residue 129 by tandemmass spectrometry. RepresentativeMS/
MS spectra of the PrP111-136 (+2) peptide from (a) rHuPrP-M129 or (b), rHuPrP-V129, and the
synthetic peptide PrP111-136 containing either methionine (c) or valine (d) at amino acid residue
129. The peptide sequence, charge state and observedm/z value for the MS1 ion are shown above
each mass spectrum. Amino acid residue 129 is underlined. Corresponding b and y ions with
observedm/z values matching those calculated in silico within the error range of the instrument
are labeled. Them/z values shown in blue are not affected by residue 129 and therefore are closely
matched between the two spectra within the error range of the instrument. By contrast, them/z
values shown in red reflect the difference in mass between the methionine and valine residues.
(TIF)
S2 Fig. Calibration curve of rHuPrP-M129 in solution with rHuPrP-V129. Recombinant
HuPrP molecules containing either M129 or V129 at codon 129 were mixed in the following
molar ratios: 0:100, 25:75, 50:50, 75:25 and 100:0 rHuPrP-M129 to rHuPrP-V129, respectively.
The mixtures were subjected to SDS-PAGE, stained with Coomassie blue and the excised
bands were digested with trypsin. Mass spectra were collected from at least 8 individual LC-MS
runs for each formulation. Spectral counts were used to determine the percentage of
rHuPrP-M129 in each mixture. Non-linear regression analysis yielded a correlation coefficient
of R2 = 0.89, indicating a good correlation between the concentration of rHuPrP-M129 in solu-
tion and spectral counts. Importantly, there was 100% specificity for the detection of each allo-
type in solutions containing only M129 or V129 rHuPrP.
(TIF)
S3 Fig. Specificity of PrPSc detection in western blot and immunohistochemistry. Immuno-
histochemistry (a) and western blot analysis (b) for PrP in frontal cortex specimens from a neg-
ative control (non-CJD) case with a pathological diagnosis of Alzheimer’s disease and vascular
dementia and a PRNP codon 129 MV genotype. Immunohistochemistry for PrP shows haema-
toxylin counter-stained nuclei (blue) but an absence of PrP staining (brown). Original magnifi-
cations X400. The PrP antibody used in immunohistochemistry was the mouse monoclonal
antibody KG9 [34]. Western blotting by the method of Parchi et al. [33] shows abundant PrP
in the absence of proteinase K digestion (-), but no PrP signal following proteinase K digestion,
even when a 10 fold increased amount of brain homogenate is loaded (+). A reference lane of
molecular mass markers (M) with their mass indicated in kilodaltons and a lane of proteinase
k treated variant CJD brain homogenate (V) are shown for reference. Frozen and fixed tissue
from this case were provided by Edinburgh Brain and Tissue Banks (11/ES/0022).
(TIF)
S1 Table. Unique PrP peptides commonly identified in a tryptic digest of heterozygous
sCJD brain tissue.
(DOC)
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S2 Table. Sub-classification of cases according to neuropathological features.
(DOC)
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